Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Stocks in this Quantisnow insightHealth Care
Historical context for JANX
Across the 17 sessions after earlier JANX headlines, the stock closed higher 9 times and lower 8 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | JANX | SPY |
|---|---|---|---|
| Aug 24, 2026 | Janux Therapeutics upgraded by Wolfe Research with a new price target | +7.0% | -0.3% |
| Aug 7, 2026 | Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights | -1.6% | +0.6% |
| May 8, 2026 | Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights | -2.5% | +0.8% |
| Apr 28, 2026 | Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development | -4.8% | -0.5% |
| Apr 20, 2026 | Janux Therapeutics downgraded by Barclays with a new price target | +0.3% | -0.2% |
| Apr 17, 2026 | Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 | +4.1% | +1.2% |
Quantisnow market dataNASDAQ
JANX
Janux Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for JANX
Full JANX profile on Quantisnow Follow JANX and get a push notification the moment its next story breaks.